 |
PDBsum entry 1xf9
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transport protein
|
PDB id
|
|
|
|
1xf9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transport protein
|
 |
|
Title:
|
 |
Structure of nbd1 from murine cftr- f508s mutant
|
|
Structure:
|
 |
Cystic fibrosis transmembrane conductance regulator. Chain: a, b, c, d. Fragment: nbd1. Synonym: cftr, camp-dependent chloride channel. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Mus musculus. House mouse. Organism_taxid: 10090. Gene: cftr, abcc7. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Octamer (from
)
|
|
Resolution:
|
 |
|
2.70Å
|
R-factor:
|
0.201
|
R-free:
|
0.253
|
|
|
Authors:
|
 |
P.H.Thibodeau,C.A.Brautigam,M.Machius,P.J.Thomas
|
Key ref:
|
 |
P.H.Thibodeau
et al.
(2005).
Side chain and backbone contributions of Phe508 to CFTR folding.
Nat Struct Mol Biol,
12,
10-16.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
14-Sep-04
|
Release date:
|
28-Dec-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P26361
(CFTR_MOUSE) -
Cystic fibrosis transmembrane conductance regulator from Mus musculus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
1476 a.a.
264 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.5.6.1.6
- channel-conductance-controlling ATPase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + H2O + closed Cl- channel = ADP + phosphate + open Cl- channel
|
 |
 |
 |
 |
 |
ATP
Bound ligand (Het Group name = )
corresponds exactly
|
+
|
H2O
|
+
|
closed Cl(-) channel
|
=
|
ADP
|
+
|
phosphate
|
+
|
open Cl(-) channel
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Nat Struct Mol Biol
12:10-16
(2005)
|
|
PubMed id:
|
|
|
|
|
| |
|
Side chain and backbone contributions of Phe508 to CFTR folding.
|
|
P.H.Thibodeau,
C.A.Brautigam,
M.Machius,
P.J.Thomas.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), an
integral membrane protein, cause cystic fibrosis (CF). The most common
CF-causing mutant, deletion of Phe508, fails to properly fold. To elucidate the
role Phe508 plays in the folding of CFTR, missense mutations at this position
were generated. Only one missense mutation had a pronounced effect on the
stability and folding of the isolated domain in vitro. In contrast, many
substitutions, including those of charged and bulky residues, disrupted folding
of full-length CFTR in cells. Structures of two mutant nucleotide-binding
domains (NBDs) reveal only local alterations of the surface near position 508.
These results suggest that the peptide backbone plays a role in the proper
folding of the domain, whereas the side chain plays a role in defining a surface
of NBD1 that potentially interacts with other domains during the maturation of
intact CFTR.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Maturation of full-length CFTR mutants.
|
 |
Figure 4.
Figure 4. ABC transporter structure and CFTR biogenesis. (a)
Crystal structure of the BtuCD ABC-transport systems21. The
Escherichia coli vitamin D transporter system BtuCD structures
(PDB entry 1L7V) are shown with the Phe508-analogous residue
Leu96 shown in red spheres at the NBD-TMD interfaces. The BtuC
transmembrane proteins are blue and the BtuD NBDs are yellow.
Two views of the BtuCD complex are shown rotated about the
vertical axis by 90°.
(b) Hierarchical folding of CFTR. Step 1, TMD1 is translated and
inserted into the membrane. Pale blue indicates the reduced
stability of TMD1 in the absence of NBD1. Step 2, NBD1 is
translated and folds into a native or near-native state. The
blurred image of the mNBD1 structure indicates the attainment of
a native or near-native state, which is most likely stabilized
by interactions with additional CFTR domains. Step 3, NBD1 docks
against TMD1. This event probably leads to the stabilization of
both NBD1 and TMD1, as shown by the change in blue color in the
TMD and the sharpening of the NBD1 structure. This is followed
by the translation, folding and assembly of the domains
C-terminal to NBD1. Mutations that putatively affect each step
are in parentheses. The NBDs are represented by the mNBD1
structure and are oriented relative to the NBD dimer and TMD
-NBD complex seen in BtuCD with the assumption that CFTR is
monomeric with a functional NBD1 -NBD2 heterodimer.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Mol Biol
(2005,
12,
10-16)
copyright 2005.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Khushoo,
Z.Yang,
A.E.Johnson,
and
W.R.Skach
(2011).
Ligand-driven vectorial folding of ribosome-bound human CFTR NBD1.
|
| |
Mol Cell,
41,
682-692.
|
 |
|
|
|
|
 |
E.Noy,
and
H.Senderowitz
(2011).
Combating Cystic Fibrosis: In Search for CF Transmembrane Conductance Regulator (CFTR) Modulators.
|
| |
ChemMedChem,
6,
243-251.
|
 |
|
|
|
|
 |
C.Wang,
I.Protasevich,
Z.Yang,
D.Seehausen,
T.Skalak,
X.Zhao,
S.Atwell,
J.Spencer Emtage,
D.R.Wetmore,
C.G.Brouillette,
and
J.F.Hunt
(2010).
Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis.
|
| |
Protein Sci,
19,
1932-1947.
|
 |
|
|
|
|
 |
G.Roy,
E.M.Chalfin,
A.Saxena,
and
X.Wang
(2010).
Interplay between ER exit code and domain conformation in CFTR misprocessing and rescue.
|
| |
Mol Biol Cell,
21,
597-609.
|
 |
|
|
|
|
 |
H.Hoelen,
B.Kleizen,
A.Schmidt,
J.Richardson,
P.Charitou,
P.J.Thomas,
and
I.Braakman
(2010).
The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain.
|
| |
PLoS One,
5,
e15458.
|
 |
|
|
|
|
 |
I.Protasevich,
Z.Yang,
C.Wang,
S.Atwell,
X.Zhao,
S.Emtage,
D.Wetmore,
J.F.Hunt,
and
C.G.Brouillette
(2010).
Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1.
|
| |
Protein Sci,
19,
1917-1931.
|
 |
|
|
|
|
 |
M.Haffke,
A.Menzel,
Y.Carius,
D.Jahn,
and
D.W.Heinz
(2010).
Structures of the nucleotide-binding domain of the human ABCB6 transporter and its complexes with nucleotides.
|
| |
Acta Crystallogr D Biol Crystallogr,
66,
979-987.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
O.Kalid,
M.Mense,
S.Fischman,
A.Shitrit,
H.Bihler,
E.Ben-Zeev,
N.Schutz,
N.Pedemonte,
P.J.Thomas,
R.J.Bridges,
D.R.Wetmore,
Y.Marantz,
and
H.Senderowitz
(2010).
Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening.
|
| |
J Comput Aided Mol Des,
24,
971-991.
|
 |
|
|
|
|
 |
S.Atwell,
C.G.Brouillette,
K.Conners,
S.Emtage,
T.Gheyi,
W.B.Guggino,
J.Hendle,
J.F.Hunt,
H.A.Lewis,
F.Lu,
I.I.Protasevich,
L.A.Rodgers,
R.Romero,
S.R.Wasserman,
P.C.Weber,
D.Wetmore,
F.F.Zhang,
and
X.Zhao
(2010).
Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant.
|
| |
Protein Eng Des Sel,
23,
375-384.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.M.Singh,
N.Kongari,
J.Cabello-Villegas,
and
K.M.Mallela
(2010).
Missense mutations in dystrophin that trigger muscular dystrophy decrease protein stability and lead to cross-beta aggregates.
|
| |
Proc Natl Acad Sci U S A,
107,
15069-15074.
|
 |
|
|
|
|
 |
V.Kanelis,
R.P.Hudson,
P.H.Thibodeau,
P.J.Thomas,
and
J.D.Forman-Kay
(2010).
NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR.
|
| |
EMBO J,
29,
263-277.
|
 |
|
|
|
|
 |
D.E.Grove,
M.F.Rosser,
H.Y.Ren,
A.P.Naren,
and
D.M.Cyr
(2009).
Mechanisms for rescue of correctable folding defects in CFTRDelta F508.
|
| |
Mol Biol Cell,
20,
4059-4069.
|
 |
|
|
|
|
 |
D.Muallem,
and
P.Vergani
(2009).
Review. ATP hydrolysis-driven gating in cystic fibrosis transmembrane conductance regulator.
|
| |
Philos Trans R Soc Lond B Biol Sci,
364,
247-255.
|
 |
|
|
|
|
 |
K.Du,
and
G.L.Lukacs
(2009).
Cooperative assembly and misfolding of CFTR domains in vivo.
|
| |
Mol Biol Cell,
20,
1903-1915.
|
 |
|
|
|
|
 |
K.J.Treharne,
Z.Xu,
J.H.Chen,
O.G.Best,
D.M.Cassidy,
D.C.Gruenert,
P.Hegyi,
M.A.Gray,
D.N.Sheppard,
K.Kunzelmann,
and
A.Mehta
(2009).
Inhibition of protein kinase CK2 closes the CFTR Cl channel, but has no effect on the cystic fibrosis mutant deltaF508-CFTR.
|
| |
Cell Physiol Biochem,
24,
347-360.
|
 |
|
|
|
|
 |
M.F.Tsai,
H.Shimizu,
Y.Sohma,
M.Li,
and
T.C.Hwang
(2009).
State-dependent modulation of CFTR gating by pyrophosphate.
|
| |
J Gen Physiol,
133,
405-419.
|
 |
|
|
|
|
 |
N.Vij,
S.Mazur,
and
P.L.Zeitlin
(2009).
CFTR is a negative regulator of NFkappaB mediated innate immune response.
|
| |
PLoS ONE,
4,
e4664.
|
 |
|
|
|
|
 |
S.Y.Huang,
D.Bolser,
H.Y.Liu,
T.C.Hwang,
and
X.Zou
(2009).
Molecular modeling of the heterodimer of human CFTR's nucleotide-binding domains using a protein-protein docking approach.
|
| |
J Mol Graph Model,
27,
822-828.
|
 |
|
|
|
|
 |
U.A.Hellmich,
and
C.Glaubitz
(2009).
NMR and EPR studies of membrane transporters.
|
| |
Biol Chem,
390,
815-834.
|
 |
|
|
|
|
 |
A.W.Serohijos,
T.Hegedus,
A.A.Aleksandrov,
L.He,
L.Cui,
N.V.Dokholyan,
and
J.R.Riordan
(2008).
Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.
|
| |
Proc Natl Acad Sci U S A,
105,
3256-3261.
|
 |
|
|
|
|
 |
A.W.Serohijos,
T.Hegedus,
J.R.Riordan,
and
N.V.Dokholyan
(2008).
Diminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfolding.
|
| |
PLoS Comput Biol,
4,
e1000008.
|
 |
|
|
|
|
 |
C.M.Deber,
J.C.Cheung,
and
A.Rath
(2008).
Defining the defect in F508 del CFTR: a soluble problem?
|
| |
Chem Biol,
15,
3-4.
|
 |
|
|
|
|
 |
J.R.Riordan
(2008).
CFTR function and prospects for therapy.
|
| |
Annu Rev Biochem,
77,
701-726.
|
 |
|
|
|
|
 |
L.S.Pissarra,
C.M.Farinha,
Z.Xu,
A.Schmidt,
P.H.Thibodeau,
Z.Cai,
P.J.Thomas,
D.N.Sheppard,
and
M.D.Amaral
(2008).
Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation.
|
| |
Chem Biol,
15,
62-69.
|
 |
|
|
|
|
 |
M.F.Rosser,
D.E.Grove,
L.Chen,
and
D.M.Cyr
(2008).
Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2.
|
| |
Mol Biol Cell,
19,
4570-4579.
|
 |
|
|
|
|
 |
N.Vij,
M.O.Amoako,
S.Mazur,
and
P.L.Zeitlin
(2008).
CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells.
|
| |
Am J Respir Cell Mol Biol,
38,
176-184.
|
 |
|
|
|
|
 |
X.Wang,
A.V.Koulov,
W.A.Kellner,
J.R.Riordan,
and
W.E.Balch
(2008).
Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking.
|
| |
Traffic,
9,
1878-1893.
|
 |
|
|
|
|
 |
A.Ahner,
K.Nakatsukasa,
H.Zhang,
R.A.Frizzell,
and
J.L.Brodsky
(2007).
Small heat-shock proteins select deltaF508-CFTR for endoplasmic reticulum-associated degradation.
|
| |
Mol Biol Cell,
18,
806-814.
|
 |
|
|
|
|
 |
J.L.Mendoza,
and
P.J.Thomas
(2007).
Building an understanding of cystic fibrosis on the foundation of ABC transporter structures.
|
| |
J Bioenerg Biomembr,
39,
499-505.
|
 |
|
|
|
|
 |
J.M.Baker,
R.P.Hudson,
V.Kanelis,
W.Y.Choy,
P.H.Thibodeau,
P.J.Thomas,
and
J.D.Forman-Kay
(2007).
CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices.
|
| |
Nat Struct Mol Biol,
14,
738-745.
|
 |
|
|
|
|
 |
K.J.Treharne,
R.M.Crawford,
Z.Xu,
J.H.Chen,
O.G.Best,
E.A.Schulte,
D.C.Gruenert,
S.M.Wilson,
D.N.Sheppard,
K.Kunzelmann,
and
A.Mehta
(2007).
Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site.
|
| |
J Biol Chem,
282,
10804-10813.
|
 |
|
|
|
|
 |
O.Zegarra-Moran,
M.Monteverde,
L.J.Galietta,
and
O.Moran
(2007).
Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators. Interaction between activation and inhibition.
|
| |
J Biol Chem,
282,
9098-9104.
|
 |
|
|
|
|
 |
S.Pagant,
L.Kung,
M.Dorrington,
M.C.Lee,
and
E.A.Miller
(2007).
Inhibiting endoplasmic reticulum (ER)-associated degradation of misfolded Yor1p does not permit ER export despite the presence of a diacidic sorting signal.
|
| |
Mol Biol Cell,
18,
3398-3413.
|
 |
|
|
|
|
 |
Y.Wang,
T.W.Loo,
M.C.Bartlett,
and
D.M.Clarke
(2007).
Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
|
| |
J Biol Chem,
282,
33247-33251.
|
 |
|
|
|
|
 |
D.C.Gadsby,
P.Vergani,
and
L.Csanády
(2006).
The ABC protein turned chloride channel whose failure causes cystic fibrosis.
|
| |
Nature,
440,
477-483.
|
 |
|
|
|
|
 |
E.J.Carlson,
D.Pitonzo,
and
W.R.Skach
(2006).
p97 functions as an auxiliary factor to facilitate TM domain extraction during CFTR ER-associated degradation.
|
| |
EMBO J,
25,
4557-4566.
|
 |
|
|
|
|
 |
F.J.Accurso
(2006).
Update in cystic fibrosis 2005.
|
| |
Am J Respir Crit Care Med,
173,
944-947.
|
 |
|
|
|
|
 |
F.Sun,
R.Zhang,
X.Gong,
X.Geng,
P.F.Drain,
and
R.A.Frizzell
(2006).
Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants.
|
| |
J Biol Chem,
281,
36856-36863.
|
 |
|
|
|
|
 |
J.M.Younger,
L.Chen,
H.Y.Ren,
M.F.Rosser,
E.L.Turnbull,
C.Y.Fan,
C.Patterson,
and
D.M.Cyr
(2006).
Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator.
|
| |
Cell,
126,
571-582.
|
 |
|
|
|
|
 |
L.Cui,
L.Aleksandrov,
Y.X.Hou,
M.Gentzsch,
J.H.Chen,
J.R.Riordan,
and
A.A.Aleksandrov
(2006).
The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating.
|
| |
J Physiol,
572,
347-358.
|
 |
|
|
|
|
 |
L.G.Randles,
I.Lappalainen,
S.B.Fowler,
B.Moore,
S.J.Hamill,
and
J.Clarke
(2006).
Using model proteins to quantify the effects of pathogenic mutations in Ig-like proteins.
|
| |
J Biol Chem,
281,
24216-24226.
|
 |
|
|
|
|
 |
M.Mense,
P.Vergani,
D.M.White,
G.Altberg,
A.C.Nairn,
and
D.C.Gadsby
(2006).
In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer.
|
| |
EMBO J,
25,
4728-4739.
|
 |
|
|
|
|
 |
S.L.Rebelo,
S.E.Bainbridge,
M.R.Amel-Kashipaz,
P.M.Radford,
R.J.Powell,
I.Todd,
and
P.J.Tighe
(2006).
Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function.
|
| |
Arthritis Rheum,
54,
2674-2687.
|
 |
|
|
|
|
 |
B.Kleizen,
T.van Vlijmen,
H.R.de Jonge,
and
I.Braakman
(2005).
Folding of CFTR is predominantly cotranslational.
|
| |
Mol Cell,
20,
277-287.
|
 |
|
|
|
|
 |
C.M.Farinha,
and
M.D.Amaral
(2005).
Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin.
|
| |
Mol Cell Biol,
25,
5242-5252.
|
 |
|
|
|
|
 |
J.E.Moody,
and
P.J.Thomas
(2005).
Nucleotide binding domain interactions during the mechanochemical reaction cycle of ATP-binding cassette transporters.
|
| |
J Bioenerg Biomembr,
37,
475-479.
|
 |
|
|
|
|
 |
J.Oberdorf,
D.Pitonzo,
and
W.R.Skach
(2005).
An energy-dependent maturation step is required for release of the cystic fibrosis transmembrane conductance regulator from early endoplasmic reticulum biosynthetic machinery.
|
| |
J Biol Chem,
280,
38193-38202.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |